Chemical substructures that enrich for biological activity

Motivation: Certain chemical substructures are present in many drugs. This has led to the claim of ‘privileged’ substructures which are predisposed to bioactivity. Because bias in screening library construction could explain this phenomenon, the existence of privilege has been controversial. Results: Using diverse phenotypic assays, we defined bioactivity for multiple compound libraries. Many substructures were associated with bioactivity even after accounting for substructure prevalence in the library, thus validating the privileged substructure concept. Determinations of privilege were confirmed in independent assays and libraries. Our analysis also revealed ‘underprivileged’ substructures and ‘conditional privilege’—rules relating combinations of substructure to bioactivity. Most previously reported substructures have been flat aromatic ring systems. Although we validated such substructures, we also identified three-dimensional privileged substructures. Most privileged substructures display a wide variety of substituents suggesting an entropic mechanism of privilege. Compounds containing privileged substructures had a doubled rate of bioactivity, suggesting practical consequences for pharmaceutical discovery. Contact: fritz_roth@hms.harvard.edu Supplementary information: Supplementary data are available at Bioinformatics online.

[1]  Peter Gregor,et al.  E-mail interfaces for older people , 2004, 2004 IEEE International Conference on Systems, Man and Cybernetics (IEEE Cat. No.04CH37583).

[2]  A Michiel van Rhee.  Use of recursion forests in the sequential screening process: consensus selection by multiple recursion trees. , 2003, Journal of chemical information and computer sciences.

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[4]  M E Mount,et al.  Mechanism of diphacinone rodenticide toxicosis in the dog and its therapeutic implications. , 1983, American journal of veterinary research.

[5]  D. Richardson,et al.  The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. , 2003, Carcinogenesis.

[6]  Richard D. O'Brien,et al.  The Receptors : a comprehensive treatise , 1979 .

[7]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[8]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[9]  W. C. Ripka,et al.  Protein β-turn mimetics I. Design, synthesis, and evaluation in model cyclic peptides. , 1993 .

[10]  Arthur A. Patchett,et al.  Chapter 26. Privileged structures — An update , 2000 .

[11]  Mark L. Smythe,et al.  Exploring privileged structures: the combinatorial synthesis of cyclic peptides , 2002, J. Comput. Aided Mol. Des..

[12]  Lawrence B. Holder,et al.  Mining Graph Data , 2006 .

[13]  Markus Wagener,et al.  Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features , 2000, J. Chem. Inf. Comput. Sci..

[14]  Marsha Penman,et al.  Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B Samuelsson,et al.  Solid-phase synthesis of libraries generated from a 4-phenyl-2-carboxy-piperazine scaffold. , 2001, Journal of combinatorial chemistry.

[16]  Luca Scorrano,et al.  A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. , 2002, Cancer cell.

[17]  Stuart L. Schreiber,et al.  Identifying Biologically Active Compound Classes Using Phenotypic Screening Data and Sampling Statistics , 2005, J. Chem. Inf. Model..

[18]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[19]  S. Dwight,et al.  Predicting gene function from patterns of annotation. , 2003, Genome research.

[20]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[21]  Kenneth A. Jacobson,et al.  Probing adenosine and P2 receptors: Design of novel purines and nonpurines as selective ligands , 2001, Drug development research.

[22]  G. McGaughey,et al.  pi-Stacking interactions. Alive and well in proteins. , 1998, The Journal of biological chemistry.

[23]  P. Andrews,et al.  Molecular conformation and biological activity of central nervous system active drugs , 1982, Medicinal research reviews.

[24]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. , 1999, Blood.

[25]  Randall W King,et al.  Small Molecule Regulators of Protein Arginine Methyltransferases* , 2004, Journal of Biological Chemistry.

[26]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[27]  Joost N. Kok,et al.  Frequent graph mining and its application to molecular databases , 2004, 2004 IEEE International Conference on Systems, Man and Cybernetics (IEEE Cat. No.04CH37583).

[28]  S. Haggarty,et al.  Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. , 2000, Chemistry & biology.

[29]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G-Protein-Coupled Receptors , 2002 .

[30]  D. Johnston,et al.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Robert P. Sheridan.  Finding Multiactivity Substructures by Mining Databases of Drug-Like Compounds , 2003, J. Chem. Inf. Comput. Sci..

[32]  H S Rosenkranz,et al.  Evaluating the ability of CASE, an artificial intelligence structure-activity relational system, to predict structural alerts for genotoxicity. , 1990, Mutagenesis.

[33]  D. Hawkins,et al.  Analysis of a 2(9) full factorial chemical library. , 1995, Journal of medicinal chemistry.

[34]  Robert H. Poppenga,et al.  Confirmation of Indandione Rodenticide Toxicoses by Mass Spectrometry/Mass Spectrometry , 1992, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[35]  Timothy J Mitchison,et al.  Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. , 2005, Chemistry & biology.

[36]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[37]  Nir Friedman,et al.  Learning Bayesian Networks with Local Structure , 1996, UAI.

[38]  M. Shearer,et al.  Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification , 2000, Current opinion in clinical nutrition and metabolic care.

[39]  Kai Long,et al.  A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. , 2005, Science.

[40]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[41]  H. Fales,et al.  Purification of a benzodiazepine from bovine brain and detection of benzodiazepine-like immunoreactivity in human brain. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Andrew Rusinko,et al.  Optimization of focused chemical libraries using recursive partitioning. , 2002, Combinatorial chemistry & high throughput screening.

[43]  Ashutosh P Jadhav,et al.  Exo1: A new chemical inhibitor of the exocytic pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Christophe G. Lambert,et al.  Analysis of a Large Structure/Biological Activity Data Set Using Recursive Partitioning , 1999, J. Chem. Inf. Comput. Sci..

[45]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[46]  Douglas A. Horton,et al.  The combinatorial synthesis of bicyclic privileged structures or privileged substructures. , 2003, Chemical reviews.

[47]  K. Chan,et al.  Benzodiazepine peptidomimetic inhibitors of farnesyltransferase. , 1994, Bioorganic & medicinal chemistry.

[48]  A. Garnier-Suillerot,et al.  A Structural Model for the Open Conformation of the mdr1 P-glycoprotein Based on the MsbA Crystal Structure* , 2003, Journal of Biological Chemistry.

[49]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Chapman,et al.  Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.

[51]  H Matter,et al.  Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[52]  Ferenc Csizmadia.  JChem: Java Applets and Modules Supporting Chemical Database Handling from Web Browsers , 2000, J. Chem. Inf. Comput. Sci..

[53]  K. Tsao,et al.  2-Aryl indole NK1 receptor antagonists: optimisation of the 2-aryl ring and the indole nitrogen substituent. , 2001, Bioorganic & medicinal chemistry letters.

[54]  Makoto Kinoshita,et al.  [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[55]  T. Mitchison,et al.  Phenotypic screening of small molecule libraries by high throughput cell imaging. , 2003, Combinatorial chemistry & high throughput screening.

[56]  Lawrence B. Holder,et al.  Mining Graph Data: Cook/Mining Graph Data , 2006 .

[57]  R. Desimone,et al.  Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.

[58]  G. Müller,et al.  Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.

[59]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[60]  D. Richardson,et al.  Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. , 2004, Blood.